Open Nav

20/20 GeneSystems, Inc.

Reg. A+ (Series B) Financing Round

  • Date:Thursday, October 18
  • Time:10:00 AM - 10:15 AM
  • Room:Elizabethan B
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:20/20 is now marketing in the U.S. the first multi-cancer screening blood tests powered by machine learning algorithms built from real-world data of tens of thousands of individuals screened for cancer over 15 years.
  • Company
  • Company HQ City:Rockville
  • Company HQ Country:United States
  • Company HQ State:Maryland                  
  • CEO/Top Company Official:Jonathan Cohen
  • Main Therapeutic Focus:Digital Health
  • Lead Product in Development :OneTest for the early detection of multiple cancers
  • Development Phase of Primary Product:Multiple Products in Market
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :1
  • Additional Information/Comments:20/20 is one of the first life science companies to become Qualified by the SEC under Regulation A (Reg. A+) of the JOBS Act. We have successfully raised over $3 million through equity crowdfunding through September 2018 with another $2 million expected by year end.
  • Previous and Current Investors:Ping An Ventures (China's largest digital health player); Keiretsu Forum; Equity Crowdfunding
  • Size of Last Investment Round:$7 million
  • Total Amount Raised to Date, In All Rounds:$7 million